Please Wait.....
Report
Nasal Polyposis - Epidemiology Forecast - 2032
Market Report I 2022-08-01 I 80 Pages I DelveInsight
DelveInsight's 'Nasal Polyposis - Epidemiology Forecast-2032' report delivers an in-depth understanding of Nasal Polyposis, historical and forecasted epidemiology as well as Nasal Polyposis trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Nasal Polyposis Disease Understanding
Nasal Polyposis/Nasal polyps are small, benign drop-like growths appearing in the mucosa (lining tissues) of the nose and may block the nasal passageway. Nasal Polyposis tends to be present on both sides of the nasal cavity. Small Nasal Polyposis may not reflect any symptoms, but the larger growths or groups of Nasal Polyposis can block the nasal passages or lead to breathing problems, a lost sense of smell, and frequent infections. One-sided Nasal Polyposis may need to be investigated further as they might be malignant nasal or sinus tumors.
Nasal Polyposis are a subgroup of chronic rhinosinusitis. Chronic rhinosinusitis is a condition where the nasal cavity and sinuses are inflamed for more than 4 to 12 weeks. Patients suffering from chronic rhinosinusitis condition can be progressed into chronic rhinosinusitis with NP (CRSwNP), and chronic rhinosinusitis without NP (CRSsNP). Only a portion of chronic rhinosinusitis will develop Nasal Polyposis. CRSwNP is a potentially debilitating condition in adults that are characterized by inflammation of the nose and paranasal sinuses with the presence of Nasal Polyposis.
People with a history of chronic sinus infections, allergic rhinitis, asthma, cystic fibrosis, sensitivity to NSAIDs like ibuprofen and aspirin, and Churg-Strauss syndrome are more prone to getting Nasal Polyposis. Patients suffering from NP may experience chronic nasal congestion, running nose, postnasal drip, reduced sense of smell and taste, difficulty in breathing, pressure in the face or forehead area, snoring, sleep apnea, and others.
Nasal Polyposis Diagnosis
The diagnosis of Nasal Polyps is based on a combination of history, physical examination, and often a sinus CT scan. The history of nasal congestion and loss of smell points to Nasal Polyps. Nasal examination often by nasal endoscopy confirms the diagnosis of nasal polyps and distinguishes patients with CRSwNP from patients with CRSwNP. A sinus CT scan is helpful because it documents the extent of sinus disease.
Continued in the report..
Nasal Polyposis Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by prevalent cases of chronic rhinosinusitis, diagnosed prevalent cases of chronic rhinosinusitis, diagnosed prevalent cases of Nasal Polyposis, and gender-specific diagnosed prevalent cases of Nasal Polyposis, the scenario of Nasal Polyposis in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.
Nasal Polyposis Detailed Epidemiology Segmentation
- The total prevalent cases of chronic rhinosinusitis in the 7MM were found to be 69,550,461 cases in 2021. The prevalent cases of chronic rhinosinusitis are expected to rise by 2032.
- Among all the 7MM countries, the United States accounted for the highest diagnosed prevalent cases (8,691,874 cases) of chronic rhinosinusitis in 2021.
- In 2021, the total reported diagnosed prevalent cases of Nasal Polyposis in the 7MM countries were 4,358,603 cases which are expected to increase by 2032.
- In 2021, Germany accounted for the highest number of Nasal Polyposis diagnosed prevalent cases (617,716 cases), followed by the United Kingdom (435,157 cases) among EU-5 countries. In contrast, Spain accounted for the lowest number of Nasal Polyposis diagnosed prevalent cases in EU-5.
- As per DelveInsight analysis, in Japan, most of the diagnosed prevalent cases of Nasal Polyposis were reported in males. In 2021, there were 111,545 diagnosed prevalent cases of Nasal Polyposis among males and 91,264 cases among females in Japan.
Scope of the Report
- The report covers a descriptive overview of Nasal Polyposis, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- The report assesses the disease risk and burden of Nasal Polyposis.
- The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
- The report provides the segmentation of the disease epidemiology for 7MM, a total number of prevalent cases of chronic rhinosinusitis, diagnosed prevalent cases of chronic rhinosinusitis, diagnosed prevalent cases of Nasal Polyposis, and gender-specific diagnosed prevalent cases of Nasal Polyposis.
Report Highlights
- 11-Year Forecast of Nasal Polyposis
- The 7MM Coverage
- Prevalent cases of chronic rhinosinusitis
- Diagnosed prevalent cases of chronic rhinosinusitis
- Diagnosed prevalent cases of Nasal Polyposis
- Gender-specific diagnosed prevalent cases of Nasal Polyposis
Key Questions Answered
- What are the disease risk and burdens of Nasal Polyposis?
- What is the historical Nasal Polyposis patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
- What would be the forecasted patient pool of Nasal Polyposis at the 7MM level?
- What will be the growth opportunities across the 7MM concerning the patient population for Nasal Polyposis?
- Out of the above-mentioned countries, which country would have the highest diagnosed prevalent population of Nasal Polyposis during the forecast period (2022-2032)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?
Reasons to Buy
The Nasal Polyposis report will allow the user to -
- Develop business strategies by understanding the trends shaping and driving the 7MM Nasal Polyposis epidemiology forecast.
- The Nasal Polyposis epidemiology report and model were written and developed by Master's and Ph.D. level epidemiologists.
- The Nasal Polyposis epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Geographies Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
1. Key Insights
2. Report Introduction
3. NP Epidemiology Overview at a Glance
3.1. Patient Share (%) Distribution of NP in 2019
3.2. Patient Share (%) Distribution of NP in 2032
4. Executive Summary of NP Epidemiology
5. Disease Background and Overview
5.1. Introduction to NP
5.2. Signs and Symptoms
5.3. Etiology
5.4. Causes
5.5. Pathogenesis
5.6. Diagnostic Approach
5.6.1. JESREC Score Criteria for the Diagnosis of Eosinophilic Chronic Rhinosinusitis
5.6.2. Diagnostic Algorithm
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Methodology of Epidemiology
6.3. Assumptions and Rationale: the 7MM
6.3.1. The US
6.3.2. The EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
6.3.3. Japan
6.4. Total Diagnosed Prevalent Cases of CRS in the 7MM
6.4.1. Total Diagnosed Prevalent Cases of NP in the 7MM
6.5. The United States
6.5.1. Prevalent Cases of CRS in the US
6.5.2. Diagnosed Prevalent Cases of CRS in the US
6.5.3. Diagnosed Prevalent Cases of NP in the US
6.5.4. Gender-specific Diagnosed Prevalent Cases of NP in the US
6.6. The Five European Countries
6.6.1. Germany
6.6.1.1. Prevalent Cases of CRS in Germany
6.6.1.2. Diagnosed Prevalent Cases of CRS in Germany
6.6.1.3. Diagnosed Prevalent Cases of NP in Germany
6.6.1.4. Gender-specific Diagnosed Prevalent Cases of NP in Germany
6.6.2. France
6.6.2.1. Prevalent Cases of CRS in France
6.6.2.2. Diagnosed Prevalent Cases of CRS in France
6.6.2.3. Diagnosed Prevalent Cases of NP in France
6.6.2.4. Gender-specific Diagnosed Prevalent Cases of NP in France
6.6.3. Italy
6.6.3.1. Prevalent Cases of CRS in Italy
6.6.3.2. Diagnosed Prevalent Cases of CRS in Italy
6.6.3.3. Diagnosed Prevalent Cases of NP in Italy
6.6.3.4. Gender-specific Diagnosed Prevalent Cases of NP in Italy
6.6.4. Spain
6.6.4.1. Prevalent Cases of CRS in Spain
6.6.4.2. Diagnosed Prevalent Cases of CRS in Spain
6.6.4.3. Diagnosed Prevalent Cases of NP in Spain
6.6.4.4. Gender-specific Diagnosed Prevalent Cases of NP in Spain
6.6.5. The UK
6.6.5.1. Prevalent Cases of CRS in the UK
6.6.5.2. Diagnosed Prevalent Cases of CRS in the UK
6.6.5.3. Diagnosed Prevalent Cases of NP in the UK
6.6.5.4. Gender-specific Diagnosed Prevalent Cases of NP in the UK
6.7. Japan
6.7.1. Prevalent Cases of CRS in Japan
6.7.2. Diagnosed Prevalent Cases of CRS in Japan
6.7.3. Diagnosed Prevalent Cases of NP in Japan
6.7.4. Gender-specific Diagnosed Prevalent Cases of NP in Japan
7. Patient Journey
8. Appendix
8.1. Bibliography
8.2. Abbreviations and Acronyms
8.3. Report Methodology
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
Table 1: Summary of NP Epidemiology (2019-2032)
Table 2: JESREC score criteria for the diagnosis of eosinophilic CRS
Table 3: Total Diagnosed Prevalent Cases of CRS in the 7MM, in Thousands (2019-2032)
Table 4: Total Diagnosed Prevalent Cases of NP in the 7MM, in Thousands (2019-2032)
Table 5: Prevalent Cases of CRS in the US, in Thousands (2019-2032)
Table 6: Diagnosed Prevalent Cases of CRS in the US, in Thousands (2019-2032)
Table 7: Diagnosed Prevalent Cases of NP in the US, in Thousands (2019-2032)
Table 8: Gender-specific Diagnosed Prevalent Cases of NP in the US, in Thousands (2019-2032)
Table 9: Prevalent Cases of CRS in Germany, in Thousands (2019-2032)
Table 10: Diagnosed Prevalent Cases of CRS in Germany, in Thousands (2019-2032)
Table 11: Diagnosed Prevalent Cases of NP in Germany, in Thousands (2019-2032)
Table 12: Gender-specific Diagnosed Prevalent Cases of NP in Germany, in Thousands (2019-2032)
Table 13: Prevalent Cases of CRS in France, in Thousands (2019-2032)
Table 14: Diagnosed Prevalent Cases of CRS in France, in Thousands (2019-2032)
Table 15: Diagnosed Prevalent Cases of NP in France, in Thousands (2019-2032)
Table 16: Gender-specific Diagnosed Prevalent Cases of NP in France, in Thousands (2019-2032)
Table 17: Prevalent Cases of CRS in Italy, in Thousands (2019-2032)
Table 18: Diagnosed Prevalent Cases of CRS in Italy, in Thousands (2019-2032)
Table 19: Diagnosed Prevalent Cases of NP in Italy, in Thousands (2019-2032)
Table 20: Gender-specific Diagnosed Prevalent Cases of NP in Italy, in Thousands (2019-2032)
Table 21: Prevalent Cases of CRS in Spain, in Thousands (2019-2032)
Table 22: Diagnosed Prevalent Cases of CRS in Spain, in Thousands (2019-2032)
Table 23: Diagnosed Prevalent Cases of NP in Spain, in Thousands (2019-2032)
Table 24: Gender-specific Diagnosed Prevalent Cases of NP in Spain, in Thousands (2019-2032)
Table 25: Prevalent Cases of CRS in the UK, in Thousands (2019-2032)
Table 26: Diagnosed Prevalent Cases of CRS in the UK, in Thousands (2019-2032)
Table 27: Diagnosed Prevalent Cases of NP in the UK, in Thousands (2019-2032)
Table 28: Gender-specific Diagnosed Prevalent Cases of NP in the UK, in Thousands (2019-2032)
Table 29: Prevalent Cases of CRS in Japan, in Thousands (2019-2032)
Table 30: Diagnosed Prevalent Cases of CRS in Japan, in Thousands (2019-2032)
Table 31: Diagnosed Prevalent Cases of NP in Japan, in Thousands(2019-2032)
Table 32: Gender-specific Diagnosed Prevalent Cases of NP in Japan, in Thousands (2019-2032)
Figure 1: NP in the nose and sinus cavity
Figure 2: Anatomy of normal nasal area vs. CRSwNP
Figure 3: Radiographic findings in severe CRSwNP
Figure 4: Primary symptoms of NP
Figure 5: Secondary symptoms of NP
Figure 6: Etiology of NP
Figure 7: Causes of NP
Figure 8: Hypothetical timeline and interactions of events in the formation of NP
Figure 9: Differential diagnosis of NP
Figure 10: Diagnostic algorithm of refractory CRS
Figure 11: Four-step diagnosis of sinonasal disorders
Figure 12: Diagnostic Algorithm in NP
Figure 13: Total Diagnosed Prevalent Cases of CRS in the 7MM (2019-2032)
Figure 14: Total Diagnosed Prevalent Cases of NP in the 7MM (2019-2032)
Figure 15: Prevalent Cases of CRS in the US (2019-2032)
Figure 16: Diagnosed Prevalent Cases of CRS in the US (2019-2032)
Figure 17: Diagnosed Prevalent Cases of NP in the US (2019-2032)
Figure 18: Gender-specific Diagnosed Prevalent Cases of NP in the US (2019-2032)
Figure 19: Prevalent Cases of CRS in Germany (2019-2032)
Figure 20: Diagnosed Prevalent Cases of CRS in Germany (2019-2032)
Figure 21: Diagnosed Prevalent Cases of NP in Germany (2019-2032)
Figure 22: Gender-specific Diagnosed Prevalent Cases of NP in Germany (2019-2032)
Figure 23: Prevalent Cases of CRS in France (2019-2032)
Figure 24: Diagnosed Prevalent Cases of CRS in France (2019-2032)
Figure 25: Diagnosed Prevalent Cases of NP in France (2019-2032)
Figure 26: Gender-specific Diagnosed Prevalent Cases of NP in France (2019-2032)
Figure 27: Prevalent Cases of CRS in Italy (2019-2032)
Figure 28: Diagnosed Prevalent Cases of CRS in Italy (2019-2032)
Figure 29: Diagnosed Prevalent Cases of NP in Italy (2019-2032)
Figure 30: Gender-specific Diagnosed Prevalent Cases of NP in Italy (2019-2032)
Figure 31: Prevalent Cases of CRS in Spain (2019-2032)
Figure 32: Diagnosed Prevalent Cases of CRS in Spain (2019-2032)
Figure 33: Diagnosed Prevalent Cases of NP in Spain (2019-2032)
Figure 34: Gender-specific Diagnosed Prevalent Cases of NP in Spain (2019-2032)
Figure 35: Prevalent Cases of CRS in the UK (2019-2032)
Figure 36: Diagnosed Prevalent Cases of CRS in the UK (2019-2032)
Figure 37: Diagnosed Prevalent Cases of NP in the UK (2019-2032)
Figure 38: Gender-specific Diagnosed Prevalent Cases of NP in the UK (2019-2032)
Figure 39: Prevalent Cases of CRS in Japan (2019-2032)
Figure 40: Diagnosed Prevalent Cases of CRS in Japan (2019-2032)
Figure 41: Diagnosed Prevalent Cases of NP in Japan (2019-2032)
Figure 42: Gender-specific Diagnosed Prevalent Cases of NP in Japan (2019-2032)
Figure 43: Patient Journey
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security